Targeted Therapy for Central Nervous System: Formulation, Clinical Challenges and Regulatory Strategies presents research on various delivery methods of drugs to the central nervous system and brain. This volume examines targeted therapies for neurodegenerative disorders and succinctly outlines the future of drug delivery systems, highlighting significant advancements specifically relating to central nervous system delivery. This book will be of great interest to researchers working in the field of neuroscience and pharmacology as well as clinicians (pharmacists, radiologists, psychiatrists).
Part I. Brief About Pathophysiology
1. Etiology and Treatment Challenges for Neurodegenerative Disorders
2. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric Disorders
3. Barriers to Progress of Neurotherapeutics: Getting Drugs to the Brain
Part II. Novel Formulation Strategies for Targeted Therapy
4. IGF-II Conjugated Nanocarrier for Brain Targeting
5. ApoE Potential in CNS Drugs Targeting and as CNS Therapeutic
6. Transferrin Functionalized Nanoparticles for Targeted Drug Delivery in Biological Systems
7. Surface Engineered Multimodal Magnetic Nanoparticles for Neurodegenerative Diseases
8. Tau Targeting Biomimetic Nanoparticles
9. Stem Cell Therapy as a Novel Concept to Combat CNS Disorders
10. SR-B1 Receptor Targeting in CNS Disorders
11. ß- and ?-secretases as Therapeutic Targets for Alzheimer’s Disease
12. Minimally Invasive Nasal Depot (MIND) Technique for Direct BDNF AntagoNAT Delivery to the Brain
13. Immunosuppressive and Immunomodulatory Therapies
14. CRISPR/Cas9 Gene Editing: A New Hope for Alzheimer’s Disease
15. Artificial Intelligence: Ways and Means for Central Nervous System (CNS) Delivery
16. Carbon Dots as Versatile Nano-architectures for the Treatment of Neurological Disorders
Part III. Clinical Challenges and Regulatory Updates
17. Animal Models for Clinical Evaluation
18. Medical Device
Contributors: Abhishek Swarnkar, Viral Patel, Amit Patel, Manan Raval
19. Regulation of Nanomaterials and Nanomedicines for Clinical Applications
20. Regulatory Considerations for the use of Biomarkers and Personalized Medicine in CNS Drug Development
21. Regulatory Toxicology Testing for Pharmaceuticals
22. Emerging Challenges and Opportunities for Drug and Drug Product Registrations
23. CRISPR/Cas9 Gene Editing: A New Hope for Parkinson’s Disease
Height:
Width:
Spine:
Weight:0.00